SyVento and OncoArendi have signed a joint development collaboration and exclusive global licensing agreement for the use of the nanoliposomal formulation of the arginase inhibitor OATD-02.
Details in following press release.
April 17, 2024
Meet our Team on LSX World Conference 2024: Bridging Innovations in Life SciencesLondon, April 29-30, 2024 The LSX World Conference, a premier event in the life sciences industry, convened today in London, bringing together global leaders, innovators, and investors to explore the latest trends and advancements in healthcare, biotechnology, and pharmaceuticals. Hosted by Informa Connect, the conference promises to be a dynamic platform for networking, knowledge exchange, […]